Third-party tested
Melanotan II
A cyclic melanocortin peptide analog of α-MSH, studied at melanocortin receptors (MC1R–MC5R) in laboratory models.
Availability: 9 in stock
Melanotan II, by the numbers.
Structural and laboratory facts that define this compound. For laboratory research use only.
Cyclic heptapeptide core
g/mol · C50H69N15O9
MC1R – MC5R melanocortin family
Asp–Lys cyclization
The Melanotan II molecule
A schematic atomic representation shown next to the compound's molecular data. The figure is illustrative, not a measured conformation.
How it is studied.
Non-selective melanocortin receptor agonism studied across pigmentation, metabolic, and sexual function research
Melanotan II (MTII) activates MC1R on melanocytes, stimulating intracellular cAMP production that drives melanogenesis — the synthesis of eumelanin (brown-black) pigment. This mechanism has been extensively studied as a model for understanding UV-independent tanning and photoprotective pigmentation pathways.
- Potent MC1R agonism drives eumelanin synthesis
- Activates adenylyl cyclase/cAMP/PKA signaling cascade
- Increases melanin production without UV exposure in models
MTII's high-affinity binding at MC4R in the hypothalamus modulates both appetite suppression and arousal-related signaling. MC4R knockout studies demonstrate these pathways are distinct. MTII's non-selective binding at MC3R and MC4R makes it a pharmacological tool for dissecting melanocortin circuit functions in energy balance research.
- MC4R activation suppresses food intake in animal models
- Modulates hypothalamic energy expenditure circuits
- Precursor to the more selective PT-141 (bremelanotide)
Unlike its derivative PT-141, Melanotan II is a non-selective melanocortin receptor agonist that activates MC1R through MC5R with varying affinities. This broad receptor activity makes it uniquely valuable as a pharmacological probe for studying the full melanocortin system in preclinical research, while also contributing to its broader side-effect profile.
- Binds MC1R, MC3R, MC4R, and MC5R
- ~1000× more potent than endogenous α-MSH at MC receptors
- Cyclic D-Phe substitution confers metabolic resistance
Research pathway map
The primary pathways Melanotan II is investigated against in laboratory models.
Compound details.
Storage & handling
Supplied as a lyophilized powder. Store the sealed vial refrigerated at 2–8°C, protected from light and moisture; −20°C for long-term storage. Keep reconstituted material refrigerated.
J Am Chem Soc · 1989Design of a new class of superpotent cyclic alpha-melanotropins based on quenched dynamic simulations
Original design of the cyclic melanotropin series.
Al-Obeidi F et al., 1989 · PubMed ↗Life Sci · 1996Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study
Early pharmacology study.
Dorr RT et al., 1996 · PubMed ↗Peptides · 2006Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization
Review of melanocortin peptide research.
Hadley ME, Dorr RT, 2006 · PubMed ↗
